Written by 
Anchiy Eli Lilly (NYSE:LLY) and privately held Incyclix Bio have agreed to work on a clinical trial together evaluating the former’s Verzenio (abemaciclib) with the latter’s INX-315 and fulvestrant as a potential treatment for HR+/HER2- breast cancer. Terms call for Lilly Source link
